Vivaldi Biosciences is developing its DeltaFLU influenza vaccine to provide broad cross-protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1.
R&D:Administered as a nasal spray, DeltaFLU generates a first line of defense at the point of entry of circulating viruses. In clinical trials, DeltaFLU has been shown to induce antibodies in the nasal mucosa that cross-neutralize influenza strains of different subtypes. DeltaFLU strains are replication-deficient in animals and humans and are not shed by the recipient, providing significant safety advantages.
Mariahilferstraße 101/1/21
1060 Wien
Vienna
Contact: Thomas Muster (Managing Director)
Email: thomas.muster@vivaldibiosciences.com
Website